UPADACITINIB (RINVOQ) IS AN EVOLUTION IN THE TREATMENT OF RHEUMATOID ARTHRITIS

Lukyanchuk E.

Summary. In the scientific-practical conference «Comorbidity in rheumatology: features of diagnosis and treatment», organized by the All-Ukrainian Association of Rheumatologists of Ukraine with the participation of the National Academy of Medical Sciences of Ukraine, Ministry of Health of Ukraine, SI NSC «Institute of Cardiology named after Academician M.D. Strazheska» NAMS of Ukraine, National Medical Academy of Postgraduate Education named after P.L. Shupyk of the Ministry of Health of Ukraine, NGO «All-Ukrainian Association of Researchers of Ukraine» and NGO «All-Ukrainian Association of Preventive Cardiology and Rehabilitation», took place on March 18, 2021 a symposium «Upadacitinib (RINVOQ) — evolution in the treatment of rheumatoid arthritis». The scientific moderator of the event was Kovalenko Volodymyr Mykolayovych, Academician of NAMSU, Professor, President of the All-Ukrainian Association of Rheumatologists of Ukraine, Director of the State Institute «NSC «Institute of Cardiology named after Academician MD Strazheska» of the National Academy of Medical Sciences of Ukraine.